Results 171 to 180 of about 326,728 (258)

Single-Cell Mapping of Progressive Fetal-to-Adult Transition in Human Naive T Cells. [PDF]

Cell Rep, 2021
Bunis DG, Bronevetsky Y, Krow-Lucal E, Bhakta NR, Kim CC, Nerella S, Jones N, Mendoza VF, Bryson YJ, Gern JE, Rutishauser RL, Ye CJ, Sirota M, McCune JM, Burt TD.   +14 more
europepmc   +1 more source

Lymphoid‐Tissue‐on‐Chip Recapitulates Human Antibody Responses In Vitro

Advanced Science, EarlyView.
The presented lymphoid‐tissue‐on‐chip system allows culture of primary human tonsil cells at organotypic high density under perfusion for up to 4 weeks, emulates immune response to soluble vaccines and vaccination via peripheral antigen‐presenting cells and represents a useful tool to assess cellular interactions during homeostasis, immune responses ...
Claudia Teufel, Anna‐Sophie Schlemmer, Andrea W. Eiken, Zachary W. Wagoner, Dennis Vöhringer, Lena Christ, Alex Dulovic, Patrick Marsall, Madeleine Fandrich, Eduardo J. S. Brás, Julia Marzi, Friederike Bärhold, Julia Philipp, Sven Becker, Lisa E. Wagar, Peter Loskill   +15 more
wiley   +1 more source

Pretreatment naive T cells are associated with severe irAE following PD-1/CTLA-4 checkpoint blockade for melanoma. [PDF]

JCI Insight
Marks KE, Horisberger A, Elahee M, Adejoorin IA, Ghosh N, Postow M, Donlin L, Bass AR, Rao DA.   +8 more
europepmc   +1 more source

STING Ligand-Mediated Priming of Functional CD8⁺ T Cells Specific for HIV-1-Protective Epitopes from Naive T Cells. [PDF]

J Virol, 2021
Kuse N, Akahoshi T, Takiguchi M.
europepmc   +1 more source

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

Advanced Science, EarlyView.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li, Yuanxin Li, Asif Rashid, Hong Kee Tan, Shing Chan, Man Yan Hui, Wilson Yau Ki Chan, Kee See Lam, Yinping Liu, Wenwei Tu, Wing Leung   +10 more
wiley   +1 more source

Exploring the Link Between Stress-Induced Naive T-Cells and Esophageal Squamous Cell Carcinoma Risk: A Multi-Omics Investigation. [PDF]

Ann Surg Oncol
Cheng J, Zhang D, Zhu L, Xu H, Zhao H, Zhu P, Li Y.   +6 more
europepmc   +1 more source

Correction: Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. [PDF]

J Immunother Cancer, 2023
europepmc   +1 more source

Single‐Cell Dissection of Tumor‐Infiltrating Lymphocytes Reveals Cellular Architecture Predictive of Therapeutic Efficacy in Acral Melanoma

Advanced Science, EarlyView.
Autologous tumor‐infiltrating lymphocyte (TIL) therapy shows promising efficacy in acral melanoma, yet determinants of durable response remain unclear. By integrating single‐cell transcriptomics and TCR sequencing, this study reveals that TIL products enriched for T follicular helper and intermediate exhausted T cells establish persistent clonal ...
Chao Zhang, Wanyi Xiao, Hongru Shen, Fenge Li, Ting Li, Weihong Zhang, Haotian Liu, Ziwei Gao, Hongyu Wang, Xiubao Ren, Kexin Chen, Xiangchun Li, Jilong Yang   +12 more
wiley   +1 more source

Transcriptomic rewiring of the JAK-STAT pathway in circulating CD4⁺CLA⁺ and CD4⁺ naïve T cells from patients with atopic dermatitis and psoriasis. [PDF]

Front Immunol
Pook M, Maruste R, Kolberg P, Alasoo K, Org T, Raam L, Remm A, Greco D, Federico A, Kingo K, Kisand K, Rebane A.   +11 more
europepmc   +1 more source

Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer

Advanced Science, EarlyView.
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen, Dingru Li, Yingna Liao, Zehua Wang, Chunbin Zhu, Zifeng Zhang, Liquan Jin, Yueyue Chen, Jiaoshun Chen, Junyi Xu, Miaoyan Wei, Rong Tang, Xianjun Yu, Si Shi   +13 more
wiley   +1 more source